PUBLISHER: Grand View Research | PRODUCT CODE: 1888689
PUBLISHER: Grand View Research | PRODUCT CODE: 1888689
U.S. Autism Spectrum Disorder Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Application, By Distribution Channel, And Segment Forecasts, 2025 - 2033
U.S. Autism Spectrum Disorder Treatment Market Summary
The U.S. autism spectrum disorder treatment market size was estimated at USD 827.84 million in 2024 and is projected to reach USD 1,431.60 million by 2033, growing at a CAGR of 6.30% from 2025 to 2033. The increasing diagnosis rates and wider access to therapeutic services drive the growth of the Autism Spectrum Disorder (ASD) treatment market in the U.S.
Growing awareness among caregivers, pediatricians, and educators has led to increased early screening and expedited referrals to specialized care. Treatment providers across behavioral therapy, pharmacologic care, and digital platforms are broadening their service footprint to meet the rising demand. Diagnostic refinement continues to support more precise and individualized care pathways, thereby improving overall treatment outcomes. For instance, in May 2025, the Centers for Disease Control and Prevention reported that 1 in 31 children aged 8 years (3.2%) had been identified with autism spectrum disorder, noting occurrence across all racial, ethnic, and socioeconomic groups. The agency further stated that autism was more than three times more common in boys than in girls and that 1 in 6 children aged 3-17 years (17%) had been diagnosed with a developmental disability-including autism spectrum disorder-between 2009 and 2017, with 2022 prevalence at 32.2 per 1,000 children (1 in 31).
Pharmaceutical development remains a central growth driver for the U.S. autism spectrum disorder treatment industry, as the companies focus on therapies addressing irritability, hyperactivity, and behavioral dysregulation. A robust late-stage pipeline is expected to expand treatment eligibility across both pediatric and adult populations. The integration of digital behavioral therapies into clinical pathways is enhancing consistency, scalability, and accessibility, particularly for families requiring remote interventions. Evidence-based treatment combinations, including structured behavioral programs paired with pharmacologic support, strengthen functional and social outcomes. These evolving care models are increasing the adoption of treatment across diverse patient segments.
Investment in research, data-driven technologies, and multidisciplinary care continues to shape the U.S. market's progress. Advanced analytic tools are deepening the understanding of neurobiological mechanisms, accelerating the discovery of new therapeutic targets. Strong collaboration between U.S. academic centers, clinical networks, and industry partners is enhancing trial efficiency and translational success. For instance, in May 2025, the Centers for Disease Control and Prevention reiterated that autism spectrum disorder diagnosis relies on caregiver developmental histories and behavioral assessments guided by DSM-5 criteria, which include three severity levels, namely, Level 1 requiring support, Level 2 requiring substantial support, and Level 3 requiring very substantial support. The growing use of multidisciplinary care frameworks, combining medical, behavioral, educational, and digital components, continues to reinforce a more holistic and sustainable U.S. Autism Spectrum Disorder treatment landscape.
U.S. Autism Spectrum Disorder Treatment Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. autism spectrum disorder treatment market report based on treatment type, application, and distribution channel:
- Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
- Antipsychotic Drugs
- Selective Serotonin Reuptake Inhibitors
- Stimulants
- Sleep Medications
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Autistic Disorder
- Asperger Syndrome
- Pervasive Developmental Disorder
- Others
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Treatment Type
- 1.2.2. Application
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Autism Spectrum Disorder Treatment Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. U.S. Autism Spectrum Disorder Treatment Market: Treatment Type Business Analysis
- 4.1. Treatment Type Market Share, 2024 & 2033
- 4.2. Treatment Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
- 4.4. Antipsychotic Drugs
- 4.4.1. Antipsychotic Drugs Market, 2021 - 2033 (USD Million)
- 4.5. Selective Serotonin Reuptake Inhibitors
- 4.5.1. Selective Serotonin Reuptake Inhibitors Market, 2021 - 2033 (USD Million)
- 4.6. Stimulants
- 4.6.1. Stimulants Market, 2021 - 2033 (USD Million)
- 4.7. Sleep Medications
- 4.7.1. Sleep Medications Market, 2021 - 2033 (USD Million)
- 4.8. Others
- 4.8.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. U.S. Autism Spectrum Disorder Treatment Market: Application Business Analysis
- 5.1. Application Market Share, 2024 & 2033
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 5.4. Autistic Disorder
- 5.4.1. Autistic Disorder Market, 2021 - 2033 (USD Million)
- 5.5. Asperger Syndrome
- 5.5.1. Asperger Syndrome Market, 2021 - 2033 (USD Million)
- 5.6. Pervasive Developmental Disorder
- 5.6.1. Pervasive Developmental Disorder Market, 2021 - 2033 (USD Million)
- 5.7. Others
- 5.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. U.S. Autism Spectrum Disorder Treatment Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacy
- 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacy
- 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
- 6.6. Online Pharmacy
- 6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Participant Overview
- 7.2. Company Market Position Analysis
- 7.3. Company Categorization
- 7.4. Strategy Mapping
- 7.5. Company Profiles/Listing
- 7.5.1. Johnson & Johnson (Janssen)
- 7.5.1.1. Overview
- 7.5.1.2. Financial Performance
- 7.5.1.3. Product Benchmarking
- 7.5.1.4. Strategic Initiatives
- 7.5.2. Roche (F. Hoffmann-La Roche)
- 7.5.2.1. Overview
- 7.5.2.2. Financial Performance
- 7.5.2.3. Product Benchmarking
- 7.5.2.4. Strategic Initiatives
- 7.5.3. Otsuka Pharmaceutical Co., Ltd.
- 7.5.3.1. Overview
- 7.5.3.2. Financial Performance
- 7.5.3.3. Product Benchmarking
- 7.5.3.4. Strategic Initiatives
- 7.5.4. AbbVie Inc.
- 7.5.4.1. Overview
- 7.5.4.2. Financial Performance
- 7.5.4.3. Product Benchmarking
- 7.5.4.4. Strategic Initiatives
- 7.5.5. Novartis AG
- 7.5.5.1. Overview
- 7.5.5.2. Financial Performance
- 7.5.5.3. Product Benchmarking
- 7.5.5.4. Strategic Initiatives
- 7.5.6. Eli Lilly & Company
- 7.5.6.1. Overview
- 7.5.6.2. Financial Performance
- 7.5.6.3. Product Benchmarking
- 7.5.6.4. Strategic Initiatives
- 7.5.7. Curemark LLC
- 7.5.7.1. Overview
- 7.5.7.2. Financial Performance
- 7.5.7.3. Product Benchmarking
- 7.5.7.4. Strategic Initiatives
- 7.5.8. Yamo Pharmaceuticals
- 7.5.8.1. Overview
- 7.5.8.2. Financial Performance
- 7.5.8.3. Product Benchmarking
- 7.5.8.4. Strategic Initiatives
- 7.5.9. PaxMedica
- 7.5.9.1. Overview
- 7.5.9.2. Financial Performance
- 7.5.9.3. Product Benchmarking
- 7.5.9.4. Strategic Initiatives
- 7.5.10. Merck & Co., Inc.
- 7.5.10.1. Overview
- 7.5.10.2. Financial Performance
- 7.5.10.3. Product Benchmarking
- 7.5.10.4. Strategic Initiatives
- 7.5.1. Johnson & Johnson (Janssen)
List of Tables
- Table 1 List of secondary sources
- Table 2 List of abbreviations
- Table 3 US autism spectrum disorder treatment market, by treatment type, 2021 - 2033 (USD Million)
- Table 4 US autism spectrum disorder treatment market, by application, 2021 - 2033 (USD Million)
- Table 5 US autism spectrum disorder treatment market, by distribution channel, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 U.S. autism spectrum disorder treatment market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot
- Fig. 9 Competitive landscape
- Fig. 10 U.S. autism spectrum disorder treatment market dynamics
- Fig. 11 U.S. autism spectrum disorder treatment market: Porter's five forces analysis
- Fig. 12 U.S. autism spectrum disorder treatment market: PESTLE analysis
- Fig. 13 Treatment Type market, 2021 - 2033 (USD Million)
- Fig. 14 Antipsychotic Drugs market, 2021 - 2033 (USD Million)
- Fig. 15 Selective Serotonin Reuptake Inhibitors market, 2021 - 2033 (USD Million)
- Fig. 16 Stimulants market, 2021 - 2033 (USD Million)
- Fig. 17 Sleep Medications market, 2021 - 2033 (USD Million)
- Fig. 18 Others market, 2021 - 2033 (USD Million)
- Fig. 19 Application market, 2021 - 2033 (USD Million)
- Fig. 20 Autistic Disorder market, 2021 - 2033 (USD Million)
- Fig. 21 Asperger Syndrome market, 2021 - 2033 (USD Million)
- Fig. 22 Pervasive Developmental Disorder market, 2021 - 2033 (USD Million)
- Fig. 23 Others market, 2021 - 2033 (USD Million)
- Fig. 24 Distribution Channel market, 2021 - 2033 (USD Million)
- Fig. 25 Hospital Pharmacy market, 2021 - 2033 (USD Million)
- Fig. 26 Retail Pharmacy market, 2021 - 2033 (USD Million)
- Fig. 27 Online Pharmacy market, 2021 - 2033 (USD Million)
- Fig. 28 Company categorization
- Fig. 29 Company market position analysis
- Fig. 30 Strategic framework
